Next Article in Journal
Infiltration of M2 Tumor-Associated Macrophages in Oral Squamous Cell Carcinoma Correlates with Tumor Malignancy
Next Article in Special Issue
Inhibitory Effect of a γ-Tocopherol-Rich Mixture of Tocopherols on the Formation and Growth of LNCaP Prostate Tumors in Immunodeficient Mice
Previous Article in Journal
Emerging Cancer Vaccines: The Promise of Genetic Vectors
Previous Article in Special Issue
Natural Killer T Cells Subsets in Cancer, Functional Defects in Prostate Cancer and Implications for Immunotherapy
Cancers 2011, 3(4), 3714-3725; doi:10.3390/cancers3043714
Article

DNA Methylation and the HOXC6 Paradox in Prostate Cancer

,
,
 and *
Received: 4 August 2011; in revised form: 8 September 2011 / Accepted: 22 September 2011 / Published: 27 September 2011
(This article belongs to the Special Issue Prostate Cancer)
View Full-Text   |   Download PDF [258 KB, uploaded 27 September 2011]   |   Browse Figures
Abstract: Overexpression of the classical homeobox transcription factor HOXC6 is frequent in prostate cancers and correlates with adverse clinical parameters. Since surprisingly many HOXC6 target genes are downregulated in prostate cancer, it has been posited that oncogenic effects of HOXC6 in prostate cancer may be unmasked by concurrent epigenetic downregulation of target genes exerting tumor suppressive effects. To test this hypothesis, we have studied the expression of three HOXC6 target genes, CNTN1 (encoding a cell adhesion protein), DKK3 and WIF1 (encoding WNT growth factor antagonists) as well as DNA methylation of DKK3 and WIF1. HOXC6 upregulation and association with poor prognosis were confirmed in our tissue series. The three target genes were each significantly downregulated in cancer tissues and expression of each one correlated inversely with that of HOXC6. Cases with lower WIF1 expression showed significantly earlier recurrence (p = 0.021), whereas no statistical significance was reached for CNTN1 and DKK3. Hypermethylation of DKK3 or WIF1 gene promoters was observed in a subset of cancers with downregulated expression, but was often weak. Our data support the hypothesis that HOXC6 target genes exerting tumor-suppressive effects are epigenetically downregulated in prostate cancer, but DNA methylation appears to follow or bolster rather than to cause their transcriptional inactivation.
Keywords: prostate cancer; epigenetic silencing; DNA methylation; homeobox transcription factors; WNT signaling prostate cancer; epigenetic silencing; DNA methylation; homeobox transcription factors; WNT signaling
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Export to BibTeX |
EndNote


MDPI and ACS Style

Vinarskaja, A.; Yamanaka, M.; Ingenwerth, M.; Schulz, W.A. DNA Methylation and the HOXC6 Paradox in Prostate Cancer. Cancers 2011, 3, 3714-3725.

AMA Style

Vinarskaja A, Yamanaka M, Ingenwerth M, Schulz WA. DNA Methylation and the HOXC6 Paradox in Prostate Cancer. Cancers. 2011; 3(4):3714-3725.

Chicago/Turabian Style

Vinarskaja, Anna; Yamanaka, Masanori; Ingenwerth, Marc; Schulz, Wolfgang A. 2011. "DNA Methylation and the HOXC6 Paradox in Prostate Cancer." Cancers 3, no. 4: 3714-3725.


Cancers EISSN 2072-6694 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert